Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NF-κB functions as a tumour promoter in inflammation-associated cancer

Abstract

The causes of sporadic human cancer are seldom recognized, but it is estimated that carcinogen exposure and chronic inflammation are two important underlying conditions for tumour development, the latter accounting for approximately 20% of human cancer1. Whereas the causal relationship between carcinogen exposure and cancer has been intensely investigated2, the molecular and cellular mechanisms linking chronic inflammation to tumorigenesis remain largely unresolved1. We proposed that activation of the nuclear factor κB (NF-κB), a hallmark of inflammatory responses3 that is frequently detected in tumours4,5, may constitute a missing link between inflammation and cancer. To test this hypothesis, we studied the Mdr2-knockout mouse strain, which spontaneously develops cholestatic hepatitis followed by hepatocellular carcinoma6, a prototype of inflammation-associated cancer7. We monitored hepatitis and cancer progression in Mdr2-knockout mice, and here we show that the inflammatory process triggers hepatocyte NF-κB through upregulation of tumour-necrosis factor-α (TNFα) in adjacent endothelial and inflammatory cells. Switching off NF-κB in mice from birth to seven months of age, using a hepatocyte-specific inducible IκB-super-repressor transgene, had no effect on the course of hepatitis, nor did it affect early phases of hepatocyte transformation. By contrast, suppressing NF-κB inhibition through anti-TNFα treatment or induction of IκB-super-repressor in later stages of tumour development resulted in apoptosis of transformed hepatocytes and failure to progress to hepatocellular carcinoma. Our studies thus indicate that NF-κB is essential for promoting inflammation-associated cancer, and is therefore a potential target for cancer prevention in chronic inflammatory diseases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: NF-κB activation, a prominent component of Mdr2-knockout hepatitis, is abrogated by NSAID treatment.
Figure 2: NF-κB activation in Mdr2-knockout mice is induced by paracrine TNFα.
Figure 3: Inhibition of hepatocyte NF-κB activity influences neither hepatitis nor development of the premalignant features in Mdr2-knockout mice.
Figure 4: NF-κB is dispensable for early stages of HCC development, but is critical for tumour promotion.
Figure 5: NF-κB inhibition through the IκB-super-repressor or anti-TNFα treatment results in suppression of anti-apoptotic factors.

References

  1. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867 (2002)

    Article  ADS  CAS  Google Scholar 

  2. Balmain, A. & Harris, C. C. Carcinogenesis in mouse and human cells: parallels and paradoxes. Carcinogenesis 21, 371–377 (2000)

    Article  CAS  Google Scholar 

  3. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nature Rev. Immunol. 2, 725–734 (2002)

    Article  CAS  Google Scholar 

  4. Mayo, M. W. & Baldwin, A. S. The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta 1470, M55–M62 (2000)

    CAS  PubMed  Google Scholar 

  5. Lin, A. & Karin, M. NF-κB in cancer: a marked target. Semin. Cancer Biol. 13, 107–114 (2003)

    Article  CAS  Google Scholar 

  6. Mauad, T. H. et al. Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am. J. Pathol. 145, 1237–1245 (1994)

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P. & Chisari, F. V. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 188, 341–350 (1998)

    Article  CAS  Google Scholar 

  8. Block, T. M., Mehta, A. S., Fimmel, C. J. & Jordan, R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 22, 5093–5107 (2003)

    Article  CAS  Google Scholar 

  9. De Vree, J. M. et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119, 1720–1730 (2000)

    Article  CAS  Google Scholar 

  10. Staudt, L. M. Molecular diagnosis of the hematologic cancers. N. Engl. J. Med. 348, 1777–1785 (2003)

    Article  CAS  Google Scholar 

  11. Lavon, I. et al. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-κB activation. Nature Med. 6, 573–577 (2000)

    Article  CAS  Google Scholar 

  12. Gupta, S. Hepatic polyploidy and liver growth control. Semin. Cancer Biol. 10, 161–171 (2000)

    Article  CAS  Google Scholar 

  13. Bruix, J., Boix, L., Sala, M. & Llovet, J. M. Focus on hepatocellular carcinoma. Cancer Cell 5, 215–219 (2004)

    Article  CAS  Google Scholar 

  14. Chaisson, M. L., Brooling, J. T., Ladiges, W., Tsai, S. & Fausto, N. Hepatocyte-specific inhibition of NF-κB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J. Clin. Invest. 110, 193–202 (2002)

    Article  CAS  Google Scholar 

  15. Maeda, S. et al. IKKβ is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFα. Immunity 19, 725–737 (2003)

    Article  CAS  Google Scholar 

  16. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. & Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376, 167–170 (1995)

    Article  ADS  CAS  Google Scholar 

  17. Lavon, I. et al. Nuclear factor-κB protects the liver against genotoxic stress and functions independently of p53. Cancer Res. 63, 25–30 (2003)

    CAS  PubMed  Google Scholar 

  18. Friedberg, E. C., McDaniel, L. D. & Schultz, R. A. The role of endogenous and exogenous DNA damage and mutagenesis. Curr. Opin. Genet. Dev. 14, 5–10 (2004)

    Article  CAS  Google Scholar 

  19. Wang, J. S. & Groopman, J. D. DNA damage by mycotoxins. Mutat. Res. 424, 167–181 (1999)

    Article  CAS  Google Scholar 

  20. Eferl, R. et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 112, 181–192 (2003)

    Article  CAS  Google Scholar 

  21. Ehrhardt, H. et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κB. Oncogene 22, 3842–3852 (2003)

    Article  CAS  Google Scholar 

  22. Kennedy, N. J. & Davis, R. J. Role of JNK in tumor development. Cell Cycle 2, 199–201 (2003)

    CAS  PubMed  Google Scholar 

  23. Tang, G. et al. Inhibition of JNK activation through NF-κB target genes. Nature 414, 313–317 (2001)

    Article  ADS  CAS  Google Scholar 

  24. Papa, S. et al. Gadd45 β mediates the NF-κ B suppression of JNK signalling by targeting MKK7/JNKK2. Nature Cell Biol. 6, 146–153 (2004)

    Article  CAS  Google Scholar 

  25. Greten, F. R. et al. Ikkβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004)

    Article  CAS  Google Scholar 

  26. Wilson, J. & Balkwill, F. The role of cytokines in the epithelial cancer microenvironment. Semin. Cancer Biol. 12, 113–120 (2002)

    Article  CAS  Google Scholar 

  27. Radisky, D., Hagios, C. & Bissell, M. J. Tumors are unique organs defined by abnormal signaling and context. Semin. Cancer Biol. 11, 87–95 (2001)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Mdr2-knockout mice were a gift from R. P. Oude Elferink and the TALAP1 mice were received from H. Bujard. We are grateful to N. Berger, T. Golub and N. Kidess-Bassir for technical assistance, to A. Hatzubai, O. Mandlboim, N. Lieberman, G. Kojekaro, M. Davis and H. Harel for helping with MRI, FACS, mRNA and protein analysis. We thank K. Meir and M. Oren for discussions and a critical reading of the manuscript. This research was supported by grants from the Israel Science Foundation funded by the Israel Academy for Sciences and Humanities (Center of Excellence Program), Prostate Cancer Foundation Israel—Center of Excellence, German-Israeli Foundation for Scientific Research and Development (GIF, in collaboration with H. Bujard), a grant in memory of H. and F. Brody from H. M. Krueger as trustee of a charitable trust and the Israel Cancer Research Foundation (ICRF). I.S. is supported by the Lady Davis Fellowship Trust.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Eli Pikarsky or Yinon Ben-Neriah.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pikarsky, E., Porat, R., Stein, I. et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 431, 461–466 (2004). https://doi.org/10.1038/nature02924

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature02924

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing